{"id":507674,"date":"2021-06-29T09:03:53","date_gmt":"2021-06-29T13:03:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/"},"modified":"2021-06-29T09:03:53","modified_gmt":"2021-06-29T13:03:53","slug":"turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/","title":{"rendered":"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, June  29, 2021  (GLOBE NEWSWIRE) &#8212; Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme, Inc.<\/p>\n<p>\u201cPaolo brings very valuable global financial experience to our growing team, particularly in supporting commercial organizations and product launches,\u201d said Athena Countouriotis, M.D., president and CEO. \u201cAs we build our finance organization and prepare for the potential launch of repotrectinib, we are pleased to have a veteran financial leader of Paolo\u2019s caliber joining our team.\u201d<\/p>\n<p>As CFO of Epizyme, Mr. Tombesi supported the commercial launch of Tazverik (tazemetostat) for the treatment of relapsed or refractory follicular lymphoma, and was responsible for capital funding, treasury, tax and accounting, SEC reporting, financial planning and analysis, and procurement. Prior to Epizyme, he was CFO for Insmed, Inc., where he led financial operations and preparation for the commercial launch of Arikayce (amikacin liposome inhalation suspension). From 2006 to 2014, he served in roles of increasing responsibility for Novartis, including chief financial and administrative officer of Novartis Pharmaceuticals Corporation; managing director and CFO of Novartis Japan; and CFO of the European Oncology division. Earlier in his career, he served in financial roles for Bristol Myers Squibb in the U.S. and Europe, and Unilever and Johnson &amp; Johnson in Italy.<\/p>\n<p>\u201cI am excited to join the Turning Point team at such an important point in the company\u2019s evolution, with four clinical stage assets in development and as the company prepares for potential commercialization,\u201d said Mr. Tombesi. \u201cI am so impressed with Athena, the Turning Point leadership team and its board of directors and look forward to supporting the company\u2019s continued growth.\u201d<\/p>\n<p>\n        <strong>About Turning Point Therapeutics Inc.<\/strong><br \/>\n        <br \/>Turning Point Therapeutics\u00a0is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company\u2019s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1\/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-na\u00efve and pre-treated patients. The company\u2019s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1\/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1\/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. Turning Point\u2019s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-NOtM1wQAPtPoQyAo1pAcXHc8-p1JUjEyXq-EGK9wsf_-LCdlwAf83IjDGT3jwh3FQeIIsRqAJoPq-yznbK1WR8HZ72Dfs4JlaAGvre8Lng=\" rel=\"nofollow noopener\" target=\"_blank\">www.tptherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as \u201cplans\u201d, \u201cwill\u201d, \u201cbelieves,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cgoal,\u201d \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include statements regarding the potential launch and commercialization of repotrectinib and Turning Point Therapeutics\u2019 continued growth. These forward-looking statements are based upon Turning Point Therapeutics\u2019 current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics\u2019 business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point\u2019s business and the other risks described in Turning Point Therapeutics\u2019 filings with the SEC, including its quarterly report on Form 10-Q filed with the SEC on May 5, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>Contact: <br \/>Jim Mazzola<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P1PcUEwAEuGVDwiMZn21hG0IveT4HywMTx5NQXz-SnruIxdzj2chaFSVXTNNZkOpaWwOrRZJbMQRHafE9im_M529ikNbC4pVNFh9jyo_J8jA2Y5J8R1N1sTIg65RDSfA\" rel=\"nofollow noopener\" target=\"_blank\">jim.mazzola@tptherapeutics.com<\/a><br \/>858-342-8272<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/95f1e1d0-d406-4964-b463-8814358d822a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) &#8212; Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme, Inc. \u201cPaolo brings very valuable global financial experience to our growing team, particularly in supporting commercial organizations and product launches,\u201d said Athena Countouriotis, M.D., president and CEO. \u201cAs we build our finance organization and prepare for the potential launch of repotrectinib, we are pleased to have a veteran &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-507674","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) &#8212; Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme, Inc. \u201cPaolo brings very valuable global financial experience to our growing team, particularly in supporting commercial organizations and product launches,\u201d said Athena Countouriotis, M.D., president and CEO. \u201cAs we build our finance organization and prepare for the potential launch of repotrectinib, we are pleased to have a veteran &hellip; Continue reading &quot;Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-29T13:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer\",\"datePublished\":\"2021-06-29T13:03:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/\"},\"wordCount\":826,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/\",\"name\":\"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=\",\"datePublished\":\"2021-06-29T13:03:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer - Market Newsdesk","og_description":"SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) &#8212; Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Paolo Tombesi as executive vice president and CFO, effective July 26. Mr. Tombesi brings 30 years of global financial and accounting experience to Turning Point from multiple prior financial leadership roles within biotech and pharmaceutical companies, most recently serving as CFO of Epizyme, Inc. \u201cPaolo brings very valuable global financial experience to our growing team, particularly in supporting commercial organizations and product launches,\u201d said Athena Countouriotis, M.D., president and CEO. \u201cAs we build our finance organization and prepare for the potential launch of repotrectinib, we are pleased to have a veteran &hellip; Continue reading \"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-29T13:03:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer","datePublished":"2021-06-29T13:03:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/"},"wordCount":826,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/","name":"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=","datePublished":"2021-06-29T13:03:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTkyNSM0MjczNDU3IzIxNzcyMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/turning-point-therapeutics-appoints-paolo-tombesi-as-executive-vice-president-and-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/507674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=507674"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/507674\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=507674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=507674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=507674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}